Dietary Neuroketotherapeutics for Alzheimer’s Disease: An Evidence Update and the Potential Role for Diet Quality
1
Medical Center Department of Dietetics and Nutrition, University of Kansas, Kansas City, KS 66160, USA
2
Alzheimer’s Disease Center, University of Kansas, Fairway, KS 66205, USA
3
Medical Center Department of Neurology, University of Kansas, Kansas City, KS 66160, USA
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(8), 1910; https://doi.org/10.3390/nu11081910
Received: 8 July 2019
/
Revised: 29 July 2019
/
Accepted: 13 August 2019
/
Published: 15 August 2019
(This article belongs to the Special Issue Ketogenic Dietary Therapies: Recent Findings and Future Perspectives)
Alzheimer’s disease (AD) is a devastating neurodegenerative disease with growing prevalence as the global population ages. Currently available treatments for AD have minimal efficacy and there are no proven treatments for its prodrome, mild cognitive impairment (MCI). AD etiology is not well understood and various hypotheses of disease pathogenesis are currently under investigation. A consistent hallmark in patients with AD is reduced brain glucose utilization; however, evidence suggests that brain ketone metabolism remains unimpaired, thus, there is a great deal of increased interest in the potential value of ketone-inducing therapies for the treatment of AD (neuroketotherapeutics; NKT). The goal of this review was to discuss dietary NKT approaches and mechanisms by which they exert a possible therapeutic benefit, update the evidence available on NKTs in AD and consider a potential role of diet quality in the clinical use of dietary NKTs. Whether NKTs affect AD symptoms through the restoration of bioenergetics, the direct and indirect modulation of antioxidant and inflammation pathways, or both, preliminary positive evidence suggests that further study of dietary NKTs as a disease-modifying treatment in AD is warranted.
View Full-Text
Keywords:
neuroketotherapeutics; Alzheimer’s disease; cognition; fasting; ketogenic diet; β-hydroxybutyrate; medium-chain triglyceride; bioenergetics; diet quality
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 110 KiB)
MDPI and ACS Style
Taylor, M.K.; Swerdlow, R.H.; Sullivan, D.K. Dietary Neuroketotherapeutics for Alzheimer’s Disease: An Evidence Update and the Potential Role for Diet Quality. Nutrients 2019, 11, 1910. https://doi.org/10.3390/nu11081910
AMA Style
Taylor MK, Swerdlow RH, Sullivan DK. Dietary Neuroketotherapeutics for Alzheimer’s Disease: An Evidence Update and the Potential Role for Diet Quality. Nutrients. 2019; 11(8):1910. https://doi.org/10.3390/nu11081910
Chicago/Turabian StyleTaylor, Matthew K., Russell H. Swerdlow, and Debra K. Sullivan. 2019. "Dietary Neuroketotherapeutics for Alzheimer’s Disease: An Evidence Update and the Potential Role for Diet Quality" Nutrients 11, no. 8: 1910. https://doi.org/10.3390/nu11081910
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
